SEC Form 4 · accession 0001567619-18-001677
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alan Lewis
Director
Period of report
Aug 21, 2018
Accepted (ET)
Aug 22, 2018 · 7:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 21, 2018 | S | 4,200 | $100.087 | D | 21,160 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price in column 4 is the weighted average price. The price actually received ranged from $100.07 to $100.11. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.